scholarly journals Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall Survival

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Prativa Sahoo ◽  
Paul Frankel ◽  
Julie Ressler ◽  
Margarita Gutova ◽  
Alexander J. Annala ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Neural Stem Cell ◽  
High Grade Glioma ◽  
High Grade ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

Background. The aim of this study was to correlate T1-weighted dynamic contrast-enhanced MRI- (DCE-MRI-) derived perfusion parameters with overall survival of recurrent high-grade glioma patients who received neural stem cell- (NSC-) mediated enzyme/prodrug gene therapy. Methods. A total of 12 patients were included in this retrospective study. All patients were enrolled in a first-in-human study (NCT01172964) of NSC-mediated therapy for recurrent high-grade glioma. DCE-MRI data from all patients were collected and analyzed at three time points: MRI#1—day 1 postsurgery/treatment, MRI#2— day 7 ± 3 posttreatment, and MRI#3—one-month follow-up. Plasma volume (Vp), permeability (Ktr), and leakage (λtr) perfusion parameters were calculated by fitting a pharmacokinetic model to the DCE-MRI data. The contrast-enhancing (CE) volume was measured from the last dynamic phase acquired in the DCE sequence. Perfusion parameters and CE at each MRI time point were recorded along with their relative change between MRI#2 and MRI#3 (Δ32). Cox regression was used to analyze patient survival. Results. At MRI#1 and at MRI#3, none of the parameters showed a significant correlation with overall survival (OS). However, at MRI#2, CE and λtr were significantly associated with OS (p<0.05). The relative λtr and Vp from timepoint 2 to timepoint 3 (Δ32λtr and Δ32Vp) were each associated with a higher hazard ratio (p<0.05). All parameters were highly correlated, resulting in a multivariate model for OS including only CE at MRI#2 and Δ32Vp, with an R2 of 0.89. Conclusion. The change in perfusion parameter values from 1 week to 1 month following NSC-mediated therapy combined with contrast-enhancing volume may be a useful biomarker to predict overall survival in patients with recurrent high-grade glioma.

scholarly journals Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients

2016 ◽  
Vol 58 (12) ◽  
pp. 1197-1208 ◽  
Author(s):  
Agne Ulyte ◽  
Vasileios K. Katsaros ◽  
Evangelia Liouta ◽  
Georgios Stranjalis ◽  
Christos Boskos ◽  
...  
Keyword(s):  
Prognostic Value ◽  
High Grade Glioma ◽  
High Grade ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

scholarly journals NIMG-40. USE OF DYNAMIC CONTRAST ENHANCED MRI IN PREDICTING RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi150-vi151
Author(s):  
Kathryn Nevel ◽  
Mark Schreyer ◽  
Katherine Panageas ◽  
Robert J Young ◽  
Mariza Daras
Keyword(s):  
High Grade Glioma ◽  
High Grade ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

scholarly journals Dynamic contrast-enhanced MRI of synovitis in knee osteoarthritis: repeatability, discrimination and sensitivity to change in a prospective experimental study

2021 ◽  
Author(s):  
James W. MacKay ◽  
Faezeh Sanaei Nezhad ◽  
Tamam Rifai ◽  
Joshua D. Kaggie ◽  
Josephine H. Naish ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Experimental Medicine ◽  
Sensitivity To Change ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Knee Oa ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri

Abstract Objectives Evaluate test-retest repeatability, ability to discriminate between osteoarthritic and healthy participants, and sensitivity to change over 6 months, of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) biomarkers in knee OA. Methods Fourteen individuals aged 40–60 with mild-moderate knee OA and 6 age-matched healthy volunteers (HV) underwent DCE-MRI at 3 T at baseline, 1 month and 6 months. Voxelwise pharmacokinetic modelling of dynamic data was used to calculate DCE-MRI biomarkers including Ktrans and IAUC60. Median DCE-MRI biomarker values were extracted for each participant at each study visit. Synovial segmentation was performed using both manual and semiautomatic methods with calculation of an additional biomarker, the volume of enhancing pannus (VEP). Test-retest repeatability was assessed using intraclass correlation coefficients (ICC). Smallest detectable differences (SDDs) were calculated from test-retest data. Discrimination between OA and HV was assessed via calculation of between-group standardised mean differences (SMD). Responsiveness was assessed via the number of OA participants with changes greater than the SDD at 6 months. Results Ktrans demonstrated the best test-retest repeatability (Ktrans/IAUC60/VEP ICCs 0.90/0.84/0.40, SDDs as % of OA mean 33/71/76%), discrimination between OA and HV (SMDs 0.94/0.54/0.50) and responsiveness (5/1/1 out of 12 OA participants with 6-month change > SDD) when compared to IAUC60 and VEP. Biomarkers derived from semiautomatic segmentation outperformed those derived from manual segmentation across all domains. Conclusions Ktrans demonstrated the best repeatability, discrimination and sensitivity to change suggesting that it is the optimal DCE-MRI biomarker for use in experimental medicine studies. Key Points • Dynamic contrast-enhanced MRI (DCE-MRI) provides quantitative measures of synovitis in knee osteoarthritis which may permit early assessment of efficacy in experimental medicine studies. • This prospective observational study compared DCE-MRI biomarkers across domains relevant to experimental medicine: test-retest repeatability, discriminative validity and sensitivity to change. • The DCE-MRI biomarker Ktransdemonstrated the best performance across all three domains, suggesting that it is the optimal biomarker for use in future interventional studies.

Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e15623-e15623
Author(s):  
Randy F. Sweis ◽  
Milica Medved ◽  
Shannon Towey ◽  
Greg S. Karczmar ◽  
Aytekin Oto ◽  
...  
Keyword(s):  
Renal Carcinoma ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced Mri ◽  
Dynamic Contrast Enhanced ◽  
Enhanced Mri ◽  
Contrast Enhanced ◽  
Contrast Enhanced Mri
Sign in / Sign up

Export Citation Format

Share Document